What the EU's Joint Clinical Assessment Is, and What It Does Not Decide

A Joint Clinical Assessment (JCA) is a single, EU-wide scientific review of how well a new medicine works and how safe it is, measured against the treatments patients already receive. It is produced once, at the European level, so that national authorities across Europe do not each repeat the same clinical evidence review from scratch. A JCA does not set a price, does not decide whether a health system will pay for a product, and does not rank one country's approach against another's. Those decisions remain squarely national. The framework was created by Regulation (EU) 2021/2282, the EU HTA Regulation, which began to apply on 12 January 2025.

The question a JCA actually answers

Health technology assessment (HTA) is the process by which a country decides whether a new medicine or device is worth adopting. It has historically bundled two very different questions: a clinical question (does this work better than what we have, and how safely?) and an economic question (is it worth the cost, and will we reimburse it?). The JCA carves out only the first of these and answers it once for the whole Union.

Formally, the European Commission describes a JCA as a scientific analysis of the relative effects of a health technology on health outcomes, the relative clinical effectiveness and relative safety compared with one or more existing options. The output is a report describing what the evidence shows and where it is uncertain. It deliberately stops short of a verdict on value. The report does not recommend adoption, does not score the product, and does not tell any country what to do.

PICO: the structure behind the assessment

The clinical comparison is framed using PICO, which stands for Population, Intervention, Comparator, and Outcomes. Because standard care and relevant patient groups differ across Europe, member states jointly define the PICO questions the assessment must answer, and a single JCA can carry several PICOs to reflect those national differences. The developer of the medicine then submits a dossier of evidence against that agreed scope, typically within about 90 days of receiving the final scope, timed to run alongside the European Medicines Agency's review rather than after it.

What a JCA explicitly does not decide

This is the part most often misread, so let me state it plainly. Under the Treaty on the Functioning of the European Union, Article 168(7), organizing and delivering health care, including deciding what to fund, is a national responsibility. The HTA Regulation is built to respect that boundary. Three things stay entirely with each member state.

Price. A JCA contains no economic evaluation and no cost-effectiveness modeling. What a country pays for a medicine is negotiated nationally.

Reimbursement and coverage. Whether a product enters a national formulary, for which patients, and under what conditions, is a national decision. A country can reach a different coverage conclusion than its neighbor while reading the very same JCA report.

Any ranking of systems. The JCA produces shared clinical evidence, not a league table. It does not judge whether one country's decision was better than another's.

The Regulation asks member states to give the JCA report due consideration in their national appraisals and to avoid duplicating the clinical analysis it contains. That is a requirement to take the shared evidence seriously, not an instruction to reach a particular result. The clinical report is an input; the value judgment and the funding decision are national.

A staged rollout from 2025 to 2030

The Regulation phases in by product type rather than switching on all at once. From January 2025, JCAs apply to new cancer medicines and advanced therapy medicinal products (ATMPs), the gene and cell therapies. Orphan medicinal products, those for rare diseases, are scheduled to enter scope in January 2028. All remaining centrally authorised medicinal products follow from January 2030. The first high-risk medical devices are being drawn in separately, with initial device assessments expected from 2026.

The early volume has been modest. According to an ICON analysis of the Regulation's first year, roughly ten Joint Clinical Assessments and seven Joint Scientific Consultations were handled in 2025, with a substantial step up, on the order of fifty assessments, anticipated for 2026. That same review flagged the practical strains developers describe: compressed timelines, and recurring evidence concerns such as risk of bias in single-arm or single-blinded trials, non-European trial populations, and how missing data are handled. These are questions about evidence quality, and they sit precisely where a clinical assessment belongs.

Why the distinction matters

For a patient or clinician trying to make sense of the headlines, the useful mental model is a division of labor. Europe now answers the clinical question once, which reduces duplicated work and can help evidence reach national decision-makers sooner. Each country still answers its own questions about affordability and coverage, on its own timeline, with its own budget. A JCA can find that a medicine offers a clear clinical benefit and a country can still, entirely lawfully, decline to reimburse it at a given price, or cover it only for a narrower group than the trials studied.

Reading a JCA as an EU-level approval or funding decision is the most common error, and it is a reading to correct. The assessment describes the clinical evidence. It does not decide who pays.

This article is educational and is not medical advice.